thymic-factor--circulating and Graves-Disease

thymic-factor--circulating has been researched along with Graves-Disease* in 2 studies

Other Studies

2 other study(ies) available for thymic-factor--circulating and Graves-Disease

Article	Year
[Thymic hyperplasia in a patient with Graves' disease]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2009, Volume: 56, Issue:2 Benign thymic hyperplasia (TH) is a known feature of hyperthyroidism. In most cases, thymic enlargement is minimal; however, this syndrome may occasionally appear as an appreciable anterior mediastinal mass. Recognition of the benign nature of TH and its regression following treatment of the hyperthyroidism is important to prevent unnecessary surgical procedures. We present a case of TH associated with hyperthyroidism due to Graves' disease. Topics: Animals; Antithyroid Agents; Diagnosis, Differential; Female; Graves Disease; Humans; Hyperplasia; Immunoglobulins, Thyroid-Stimulating; Indium Radioisotopes; Magnetic Resonance Imaging; Mediastinal Neoplasms; Methimazole; Radionuclide Imaging; Receptors, Thyrotropin; Somatostatin; Thymic Factor, Circulating; Thymoma; Thymus Gland; Thymus Neoplasms; Young Adult	2009
[The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter]. Terapevticheskii arkhiv, 1991, Volume: 63, Issue:10 The content of medium-weight molecular peptides (MMP), lipid peroxidation (LPO) activity, the profile of blood thyroid hormones, and radioactive iodine absorption by the thyroid were determined in 104 patients with light, moderate and grave diffuse toxic goiter (DTG). The content of MMP in the blood correlated with the gravity of DTG and thus may serve an additional test for its determination. Depending on the treatment 66 patients with DTG of medium gravity were distributed into 5 groups: group I included patients given mercazolyl, group II patients on lithium carbonate, group III patients who received mercazolyl and thymalin, group IV patients on mercazolyl and piracetam, and group V included patients given mercazolyl, thymalin and piracetam. A study was made of the blood content of MMP and LPO activity before therapy and after euthyroidism attainment. The treatment with the use of mercazolyl, thymalin and piracetam was found to produce a beneficial effect on the parameters under study and the clinical course of DTG. Topics: Adjuvants, Immunologic; Adolescent; Adult; Antithyroid Agents; Drug Therapy, Combination; Female; Graves Disease; Humans; Lipid Peroxidation; Macromolecular Substances; Male; Middle Aged; Molecular Weight; Peptides; Piracetam; Remission Induction; Thymus Hormones	1991

Article

Year

[Thymic hyperplasia in a patient with Graves' disease].

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2009, Volume: 56, Issue:2

Benign thymic hyperplasia (TH) is a known feature of hyperthyroidism. In most cases, thymic enlargement is minimal; however, this syndrome may occasionally appear as an appreciable anterior mediastinal mass. Recognition of the benign nature of TH and its regression following treatment of the hyperthyroidism is important to prevent unnecessary surgical procedures. We present a case of TH associated with hyperthyroidism due to Graves' disease.

Topics: Animals; Antithyroid Agents; Diagnosis, Differential; Female; Graves Disease; Humans; Hyperplasia; Immunoglobulins, Thyroid-Stimulating; Indium Radioisotopes; Magnetic Resonance Imaging; Mediastinal Neoplasms; Methimazole; Radionuclide Imaging; Receptors, Thyrotropin; Somatostatin; Thymic Factor, Circulating; Thymoma; Thymus Gland; Thymus Neoplasms; Young Adult

2009

[The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter].

Terapevticheskii arkhiv, 1991, Volume: 63, Issue:10

The content of medium-weight molecular peptides (MMP), lipid peroxidation (LPO) activity, the profile of blood thyroid hormones, and radioactive iodine absorption by the thyroid were determined in 104 patients with light, moderate and grave diffuse toxic goiter (DTG). The content of MMP in the blood correlated with the gravity of DTG and thus may serve an additional test for its determination. Depending on the treatment 66 patients with DTG of medium gravity were distributed into 5 groups: group I included patients given mercazolyl, group II patients on lithium carbonate, group III patients who received mercazolyl and thymalin, group IV patients on mercazolyl and piracetam, and group V included patients given mercazolyl, thymalin and piracetam. A study was made of the blood content of MMP and LPO activity before therapy and after euthyroidism attainment. The treatment with the use of mercazolyl, thymalin and piracetam was found to produce a beneficial effect on the parameters under study and the clinical course of DTG.

Topics: Adjuvants, Immunologic; Adolescent; Adult; Antithyroid Agents; Drug Therapy, Combination; Female; Graves Disease; Humans; Lipid Peroxidation; Macromolecular Substances; Male; Middle Aged; Molecular Weight; Peptides; Piracetam; Remission Induction; Thymus Hormones

1991